1. Prevention of Venous Thromboembolism
2. The Pharmacology and Management of the Vitamin K Antagonists
3. 3 J Stangier, K Rathgen, H Staehle, JM Stassen, and R. Zimmermann Pharmacodynamics, safety and pharmacokinetics after single oral administration of 10, 30, 100, 200 and 400 mg BIBR 1048 MS as drinking solution in healthy subjects: an open study, placebo-controlled, randomized, double blind at each dose level. Study no. 1160.1. Report no. U99-1502. Boehringer Ingelheim Internal Report, 2000 .
4. 4 J Stangier, K Rathgen, H Staehle, D Gansser, and R. Zimmermann Relative bioavailability of 200 mg film coated tablets of BIBR 1048 MS with or without food compared to 200 mg solution of BIBR 1048 MS given as single oral administrations to healthy subjects: a 3-way cross-over, open, partly randomised study. Study no. 1160.3. Report no. U00-1231. Boehringer Ingelheim Internal Report, 1999 .
5. Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I